Agilent Technologies, Inc. (NYSE:A) Shares Sold by Calamos Wealth Management LLC

Calamos Wealth Management LLC reduced its stake in Agilent Technologies, Inc. (NYSE:A) by 23.6% during the 4th quarter, HoldingsChannel.com reports. The fund owned 1,486 shares of the medical research company’s stock after selling 458 shares during the quarter. Calamos Wealth Management LLC’s holdings in Agilent Technologies were worth $207,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in A. OFI Invest Asset Management purchased a new stake in Agilent Technologies during the 3rd quarter worth approximately $25,000. Money Concepts Capital Corp purchased a new stake in Agilent Technologies during the 4th quarter worth approximately $26,000. MV Capital Management Inc. increased its stake in Agilent Technologies by 120.7% during the 4th quarter. MV Capital Management Inc. now owns 192 shares of the medical research company’s stock worth $27,000 after buying an additional 105 shares during the period. Ancora Advisors LLC purchased a new stake in Agilent Technologies during the 4th quarter worth approximately $34,000. Finally, Baystate Wealth Management LLC increased its stake in Agilent Technologies by 107.3% during the 4th quarter. Baystate Wealth Management LLC now owns 257 shares of the medical research company’s stock worth $36,000 after buying an additional 133 shares during the period. 87.42% of the stock is currently owned by institutional investors and hedge funds.

Agilent Technologies Stock Up 0.2 %

Shares of NYSE:A opened at $132.73 on Monday. The stock has a market cap of $38.90 billion, a P/E ratio of 31.60, a P/E/G ratio of 4.02 and a beta of 1.11. The firm has a fifty day moving average price of $141.18 and a 200 day moving average price of $129.92. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.68 and a quick ratio of 2.04. Agilent Technologies, Inc. has a 1-year low of $96.80 and a 1-year high of $151.58.

Agilent Technologies (NYSE:A) last released its earnings results on Tuesday, February 27th. The medical research company reported $1.29 EPS for the quarter, topping the consensus estimate of $1.22 by $0.07. Agilent Technologies had a net margin of 18.35% and a return on equity of 27.09%. The company had revenue of $1.66 billion during the quarter, compared to analysts’ expectations of $1.59 billion. During the same quarter last year, the business earned $1.37 EPS. The business’s revenue was down 5.5% on a year-over-year basis. Sell-side analysts predict that Agilent Technologies, Inc. will post 5.51 EPS for the current year.

Agilent Technologies Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 24th. Investors of record on Tuesday, April 2nd will be paid a $0.236 dividend. This represents a $0.94 annualized dividend and a dividend yield of 0.71%. The ex-dividend date of this dividend is Monday, April 1st. Agilent Technologies’s dividend payout ratio (DPR) is 22.38%.

Insider Activity at Agilent Technologies

In related news, Director Heidi Fields sold 1,658 shares of the firm’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $144.34, for a total value of $239,315.72. Following the completion of the sale, the director now owns 54,976 shares in the company, valued at $7,935,235.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Agilent Technologies news, Director Heidi Fields sold 1,658 shares of the firm’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $144.34, for a total transaction of $239,315.72. Following the completion of the transaction, the director now directly owns 54,976 shares in the company, valued at approximately $7,935,235.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Rodney Gonsalves sold 4,828 shares of the firm’s stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $149.00, for a total transaction of $719,372.00. Following the transaction, the vice president now owns 21,329 shares of the company’s stock, valued at $3,178,021. The disclosure for this sale can be found here. Insiders sold 61,610 shares of company stock worth $9,220,333 over the last 90 days. Company insiders own 0.33% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on A. UBS Group increased their price objective on shares of Agilent Technologies from $130.00 to $155.00 and gave the company a “neutral” rating in a research report on Wednesday, February 28th. Stifel Nicolaus raised shares of Agilent Technologies from a “hold” rating to a “buy” rating and increased their price objective for the company from $145.00 to $163.00 in a research report on Friday, April 5th. Barclays increased their price objective on shares of Agilent Technologies from $125.00 to $135.00 and gave the company an “underweight” rating in a research report on Wednesday, April 10th. Evercore ISI increased their price objective on shares of Agilent Technologies from $132.00 to $145.00 and gave the company an “in-line” rating in a research report on Thursday, April 4th. Finally, Citigroup increased their price objective on shares of Agilent Technologies from $130.00 to $145.00 and gave the company a “neutral” rating in a research report on Wednesday, February 28th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $141.29.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.